Evidence map›Paper›PMID 41214477›Full record

SynthesisVirulence2025

Effectiveness of antiviral, immunomodulatory and platelet-enhancing agents for treatment of dengue infection: A systematic review.

D G Aynekulu Mersha, F Duijff, T Langerak, M S Hakim, B Martina, M Goeijenbier, V A S H Dalm, S F L van Lelyveld, E C M van Gorp

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

D G Aynekulu MershaDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-0538-2429
F DuijffDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
T LangerakDepartment of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands.
M S HakimPostgraduate School of Molecular Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
B MartinaArtemis Bioservices and Athenavax B.V, Delft, The Netherlands.
M GoeijenbierDepartment of Intensive Care, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands.
V A S H DalmDivision of Allergy and Clinical Immunology, Department of Internal Medicine, and Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
S F L van LelyveldDepartment of Internal Medicine, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands.
E C M van GorpDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is a vector-borne infectious disease, caused by dengue virus (DENV), with a rapidly increasing incidence worldwide. With no feasible, widely applicable prevention method available in the near term, the need for an effective treatment is of great importance. This systematic review aims to provide a comprehensive overview of potential antiviral, immunomodulatory, and platelet-enhancing therapies for the treatment of DENV. This systematic review was conducted according to the PRISMA guidelines. Clinical trials that investigate treatment options for DENV in the general population were included. Twenty-six studies were included, investigating length of hospital stay (

Indexed as

Antiviral AgentsDengueImmunologic FactorsImmunomodulating AgentsCaricaDengue VirusHumansLength of StayPlant ExtractsPlatelet CountTreatment OutcomeAntiviral AgentsImmunologic FactorsImmunomodulating AgentsPlant ExtractsantiviralDengueimmunityplatelettreatment

Identifiers

PMID41214477
PMCPMC12622339

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.